<?xml version="1.0" encoding="UTF-8"?>
<p id="para210">As well as other efforts to test antivirals, including drugs once used against HIV, many groups are now evaluating the use of long-standing malaria drug chloroquine and its close cousin hydroxychloroquine. Although the drugs are no longer used in parts of the world because the malaria parasite has become highly resistant to them, in early February a 
 <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41422-020-0282-0" id="interrefs170" xmlns:xlink="http://www.w3.org/1999/xlink">study</ext-link> led by researchers at the Wuhan Institute of Virology in China showed that they demonstrate some antiviral activity in human cells. More recently, French doctors shared results of a trial in which 26 people with covid-19 were given hydroxychloroquine three times a day, in some cases alongside the antibiotic azithromycin. After 10 days, those who received the treatment reportedly 
 <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/science/article/pii/S0924857920300996" id="interrefs180" xmlns:xlink="http://www.w3.org/1999/xlink">had less virus in their blood</ext-link> than 16 people not given the medicines.
</p>
